title: Does pretreatment with proton pump inhibitors influence the eradication rate of Helicobacter pylori?
abstract: OBJECTIVE
  Pretreatment with a proton pump inhibitor (PPI) has been reported to decrease the efficacy of Helicobacter pylori (H. pylori) eradication. We compared the efficacy of an eradication regimen (lansoprazole/amoxicillin/clarithromycin) first or following pretreatment with a PPI.
  
  
  METHODS
  In this retrospective study conducted at three centers, 353 patients infected with H. pylori were treated. The H. pylori status was determined using the rapid urease test, bacterial cultures, and the histological examination of endoscopic biopsy specimens, The patients were assigned to receive an eradication regimen first or following pretreatment with a PPI. Eradication was assessed using the 13C-urea breath test more than 4 weeks after the completion of therapy.
  
  
  RESULTS
  Overall, H. pylori was eradicated in 78.8% of the cases: 79.6% in the pretreatment group, and 77.6% in the eradication first group (p = 0.6541 by chi square test). No significant difference in the eradication rates was observed between the two groups.
  
  
  CONCLUSIONS
  This retrospective study indicated that pretreatment with a PPI does not significantly reduce the efficacy of eradication therapy in patients infected with H. pylori.
authors: Gastroenterology Division, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
authors: Chikako
authors: C
authors: Tokoro
authors: Masahiko
authors: M
authors: Inamori
authors: Tomoko
authors: T
authors: Koide
authors: Hiroshi
authors: H
authors: Iida
authors: Yasunari
authors: Y
authors: Sakamoto
authors: Hiroki
authors: H
authors: Endo
authors: Kunihiro
authors: K
authors: Hosono
authors: Hirokazu
authors: H
authors: Takahashi
authors: Masato
authors: M
authors: Yoneda
authors: Hiroaki
authors: H
authors: Yasuzaki
authors: Masami
authors: M
authors: Ogawa
authors: Yasunobu
authors: Y
authors: Abe
authors: Kensuke
authors: K
authors: Kubota
authors: Satoru
authors: S
authors: Saitou
authors: Ichiro
authors: I
authors: Kawana
authors: Reikei
authors: R
authors: Matsuda
authors: Daisuke
authors: D
authors: Takahashi
authors: Atsushi
authors: A
authors: Nakajima
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000008:administration & dosage; D016009:Chi-Square Distribution; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011292:Premedication; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D012189:Retrospective Studies; D018709:Statistics, Nonparametric
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin